SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
1. Class action filed against Hims for misleading statements and illegal drug promotions. 2. Major partnership with Novo Nordisk terminated due to Hims' failure to comply with laws. 3. Hims' stock plunged 34.6% following the termination news, impacting investor trust and value. 4. Investors have until August 25, 2025, to seek lead plaintiff status in the class action. 5. Faruqi & Faruqi seeks information from former employees and whistleblowers regarding Hims.